Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

(NASDAQ:SKYE) Skye also announces completion of enrollment of 26‑week extension study; 52‑week data planned, with post‑extension 13‑week follow‑up Skye also announces completion of enrollment of 2...

How does Skye's CBeyond™ trial progress compare with similar programs from competitors, and what market share could be captured if the therapy succeeds? What does the completion of the 26‑week extension enrollment indicate about the trial’s timeline for Phase 2b or potential FDA submission? How will the upcoming 52‑week data and 13‑week follow‑up affect SKYE's near‑term stock price and valuation?
Symbol: SKYE
Clinical trials
13 days ago
Read more globenewswire

Nova Announces Proposed Private Offering of $500 Million of 0.00% Convertible Senior Notes due 2030

(NASDAQ:NVMI) REHOVOT, Israel, Sept. 2, 2025 /PRNewswire/ -- Nova (NASDAQ: NVMI), a leading innovator and a key provider of advanced metrology and process control solutions used in semiconductor ma...

At what price and yield are the notes being offered, and how does this compare to current market rates for similar zero‑coupon securities? What are the conversion terms and expected dilution for existing shareholders if the notes are converted into common equity? How will the $500 million convertible senior notes issuance affect Nova's capital structure and leverage ratios?
Symbol: NVMI
Debt
13 days ago
Read more prnewswire

Golden Arrow Reports Exciting New Gold Results from the Noemi Target at the San Pietro Project, Chile

(GRG) TSX Venture Exchange (TSX-V): GRG Frankfurt Stock Exchange (FSE): G6A OTCQB Venture Market (OTCQB): GARWF www.goldenarrowresources.com • [email protected] VANCOUVER, BC, Sept. 2, ...

How does the announced data compare with recent results from peer junior miners operating in Chile, and what could it mean for valuation multiples? What is the expected impact of the San Pietro Project’s performance on GRG’s upcoming drilling program and capital budget? How will the new gold results from the Noemi target affect Golden Arrow’s short‑term cash flow and resource estimates?
Symbol: GRG
Mining
13 days ago
Read more prnewswire

Commonwealth LNG Receives Final Non-FTA Export Authorization From DOE

(CLNG) HOUSTON, Sept. 2, 2025 /PRNewswire/ -- Commonwealth LNG ("Commonwealth" or "the Company") today announced it has received its final non-free trade agreement (non-FTA) export authorization fr...

How might this regulatory approval impact LNG supply dynamics and influence market pricing for existing contracts? What is the expected timeline to bring the 9.5 Mtpa capacity online and how does it compare to peers’ project schedules? How will the final non-FTA export authorization affect Commonwealth LNG’s projected cash flows and valuation?
Symbol: CLNG
Regulatory
13 days ago
Read more prnewswire

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

(NASDAQ:OLMA) SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the ...

What are the financial terms of the Pfizer supply agreement and could it lead to dilution, milestone payments, or significant cash inflows for Olema? How does the palazestrant + atirmociclib combination compare to existing ER+/HER2‑ therapies and competing pipelines in terms of efficacy and market potential? What is the expected timeline for trial readout and how might it drive short‑term volatility in Olema's stock?
Symbol: OLMA
Clinical trial
13 days ago
Read more globenewswire

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

(NASDAQ:BIIB) BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s...

How might this partnership with Stoke Therapeutics influence Biogen's pipeline diversification and competitive positioning in the rare neurological space? What are the potential regulatory timelines and market exclusivity for a disease‑modifying therapy in Dravet syndrome compared to existing treatments? How will the Phase 1/2a results for zorevunersen affect Biogen's valuation and upcoming earnings guidance?
Symbol: BIIB
Clinical trials
13 days ago
Read more businesswire